Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 2, Number 4—October 1996

Synopsis

New Vaccines for the Prevention of Pneumococcal Infections

Helena KäyhtyComments to Author  and Juhani Eskola
Author affiliations: National Public Health Institute, Helsinki, Finland

Main Article

Table 2

Antibody response of Finnish infants to pneumococcal conjugate vaccines administered at 2, 4, and 6 months of age*.

Geometric Mean of the Anti-PNC PS (mg/ml)
Type 6B
Type 14
Type 19F
Type 23F
Vaccine
Pre
Post
Pre
Post
Pre
Post
Pre
Post
Ref.
PncOMPC 0.17 1.30 0.42 8.27 0.34 9.85 0.28 1.90 (50)
PncCRM 0.25 0.50 0.30 2.49 0.46 1.13 0.18 0.83 (52)
PncT01-4 0.25 0.89 0.24 2.84 0.36 3.73 0.18 0.82 (56)
PncT01-8 0.20 1.28 0.30 2.56 0.56 4.23 0.22 1.03 (29)
PncD03-4 0.26 0.88 0.44 2.20 0.43 5.29 0.21 0.67 (56)
PncD03-8
0.17
1.44
0.31
4.62
0.37
4.94
0.24
1.07
(29)
PncOMP = tetravalent conjugate vaccine with a meningococcal outer membrane protein complex as a carrier
PncCRM = pentavalent oligosaccharide conjugate vaccine with CRM197 protein as a carrier
PncT01-4 = tetravalent conjugate vaccine with tetanus toxoid carrier; 1 mg of each of four polysaccharides
PncT01-8 = tetravalent conjugate vaccine with tetanus toxoid carrier; 1 mg of each of four polysaccharides
PncD03-4 = tetravalent conjugate vaccine with diphtheria toxoid carrier; 3mg of each of four polysaccharides
PncD03-8 = octavalent conjugate vaccine with diphtheria toxoid carrier; 3mg of each of four polysaccharides
*Serum samples are taken before immunization (pre) and at 7 months (post). The data have been gathered from separate studies done in the same population.

Main Article

TOP